{"nctId":"NCT00094458","briefTitle":"Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease naï¿½ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC","startDateStruct":{"date":"2005-03"},"conditions":["Crohn Disease"],"count":508,"armGroups":[{"label":"003","type":"EXPERIMENTAL","interventionNames":["Other: infliximab (IFX) infusion; azathioprine (AZA) caps"]},{"label":"001","type":"EXPERIMENTAL","interventionNames":["Drug: infliximab (IFX) placebo infusion; azathioprine (AZA) caps"]},{"label":"002","type":"EXPERIMENTAL","interventionNames":["Biological: infliximab infusion; AZA placebo caps"]}],"interventions":[{"name":"infliximab infusion; AZA placebo caps","otherNames":[]},{"name":"infliximab (IFX) infusion; azathioprine (AZA) caps","otherNames":[]},{"name":"infliximab (IFX) placebo infusion; azathioprine (AZA) caps","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of Crohns Disease for at least 6 weeks\n* Moderate to severe disease activity (CDAI \\>= 220 and \\<=450)\n* No history of azathioprine, 6-MP (6 Mercaptopurine), or biologic treatments\n* Are either: Corticosteriod-dependent, OR considered for a 2nd (or greater) course of corticosteriod, OR 5-ASA failures, Or Budesonide failures\n\nExclusion Criteria:\n\n* History of abdominal surgery within the last 6 months\n* Have an ostomy or stoma \\[An operation to create an opening from an area inside the body to the outside\\]\n* Are pregnant, nursing, or planning pregnancy (both men and women)\n* Serious simultaneous illness that could interfere with study participation\n* Use of any investigational drug within 30 days\n* Have a concomitant diagnosis or any history of congestive heart failure\n* Weigh more than 140 kilograms (or 310 pounds)","healthyVolunteers":false,"sex":"ALL","minimumAge":"21 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Corticosteriod-free Clinical Remission","description":"Corticosteroid-free clinical remission is defined as a Crohn's Disease Activity Index (CDAI) less than (\\<) 150 in participants who have not received any dose of systemic corticosteroids (prednisone or equivalent) for greater than or equal to (\\>=) 3 weeks and have not received budesonide at a dose \\> 6 milligram per day (mg/day) for \\>= 3 weeks. The total CDAI score ranges from 0 - 600. The lower the CDAI score, the better (i.e., 0 is better and 600 is worse).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.0","spread":null},{"groupId":"OG001","value":"44.4","spread":null},{"groupId":"OG002","value":"56.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Mucosal Healing","description":"Complete absence of mucosal ulcerations in the colon and terminal ileum as assessed by video endoscopy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","spread":null},{"groupId":"OG001","value":"30.1","spread":null},{"groupId":"OG002","value":"43.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Corticosteroid-free Clinical Remission (Study Extension)","description":"Corticosteroid-free clinical remission is defined as a Crohn's Disease Activity Index (CDAI) \\< 150 who have not received any dose of systemic corticosteroids (prednisone or equivalent) for \\>= 3 weeks and have not received budesonide at a dose \\> 6 milligram per day (mg/day) for \\>= 3 weeks. The total CDAI score ranges from 0 - 600. The lower the CDAI score, the better (i.e., 0 is better and 600 is worse).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.7","spread":null},{"groupId":"OG001","value":"60.8","spread":null},{"groupId":"OG002","value":"72.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Clinical Remission (Main Study)","description":"Clinical remission is defined as a CDAI \\< 150, compared to baseline (Week 0)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.6","spread":null},{"groupId":"OG001","value":"32.5","spread":null},{"groupId":"OG002","value":"36.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.6","spread":null},{"groupId":"OG001","value":"49.1","spread":null},{"groupId":"OG002","value":"52.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.1","spread":null},{"groupId":"OG001","value":"47.3","spread":null},{"groupId":"OG002","value":"59.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.5","spread":null},{"groupId":"OG001","value":"49.7","spread":null},{"groupId":"OG002","value":"60.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.8","spread":null},{"groupId":"OG001","value":"47.9","spread":null},{"groupId":"OG002","value":"60.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Clinical Remission (Study Extension)","description":"Clinical remission is defined as a CDAI \\< 150, compared to baseline (Week 0)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.3","spread":null},{"groupId":"OG001","value":"66.0","spread":null},{"groupId":"OG002","value":"69.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.7","spread":null},{"groupId":"OG001","value":"72.2","spread":null},{"groupId":"OG002","value":"73.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.7","spread":null},{"groupId":"OG001","value":"66.0","spread":null},{"groupId":"OG002","value":"74.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Clinical Response Over Time (Main Study)","description":"Clinical response, defined as a \\>=100-point decrease in CDAI from Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.4","spread":null},{"groupId":"OG001","value":"42.6","spread":null},{"groupId":"OG002","value":"47.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.6","spread":null},{"groupId":"OG001","value":"54.4","spread":null},{"groupId":"OG002","value":"63.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.4","spread":null},{"groupId":"OG001","value":"55.6","spread":null},{"groupId":"OG002","value":"69.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.8","spread":null},{"groupId":"OG001","value":"55.0","spread":null},{"groupId":"OG002","value":"62.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.6","spread":null},{"groupId":"OG001","value":"54.4","spread":null},{"groupId":"OG002","value":"62.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Clinical Response Over Time (Study Extension)","description":"Clinical response, defined as a \\>=100-point decrease in CDAI from Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"76.3","spread":null},{"groupId":"OG002","value":"76.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.3","spread":null},{"groupId":"OG001","value":"74.2","spread":null},{"groupId":"OG002","value":"77.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.7","spread":null},{"groupId":"OG001","value":"72.2","spread":null},{"groupId":"OG002","value":"78.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Weeks 2, 6, 10, 18 and 26 (Main Study)","description":"Quality of life as measured by the Inflammatory Bowel Disease Questionnaire (IBDQ). The IBDQ is a 32- item questionnaire and the total IBDQ score can range from 32 (very poor) to 224 (perfect).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.1","spread":"24.29"},{"groupId":"OG001","value":"27.7","spread":"26.08"},{"groupId":"OG002","value":"31.4","spread":"29.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.3","spread":"31.25"},{"groupId":"OG001","value":"34.8","spread":"31.79"},{"groupId":"OG002","value":"39.9","spread":"32.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.0","spread":"31.66"},{"groupId":"OG001","value":"37.8","spread":"35.56"},{"groupId":"OG002","value":"42.4","spread":"34.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.3","spread":"33.92"},{"groupId":"OG001","value":"39.9","spread":"34.17"},{"groupId":"OG002","value":"43.7","spread":"34.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.4","spread":"35.43"},{"groupId":"OG001","value":"39.9","spread":"36.62"},{"groupId":"OG002","value":"45.2","spread":"35.76"}]}]}]},{"type":"SECONDARY","title":"Average Corticosteroid Use","description":"Average daily dose of systemic corticosteroid concomitant medications(prednisone or equivalent)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.92","spread":"12.476"},{"groupId":"OG001","value":"21.20","spread":"11.883"},{"groupId":"OG002","value":"22.75","spread":"11.923"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.56","spread":"11.588"},{"groupId":"OG001","value":"17.68","spread":"10.993"},{"groupId":"OG002","value":"18.26","spread":"11.635"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.19","spread":"11.160"},{"groupId":"OG001","value":"15.68","spread":"14.924"},{"groupId":"OG002","value":"15.01","spread":"11.087"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.49","spread":"10.929"},{"groupId":"OG001","value":"13.23","spread":"17.206"},{"groupId":"OG002","value":"11.64","spread":"10.904"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.57","spread":"10.246"},{"groupId":"OG001","value":"10.96","spread":"15.990"},{"groupId":"OG002","value":"9.35","spread":"10.052"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":39,"n":161},"commonTop":["Nausea","Abdominal Pain","Fatigue","Arthralgia","Headache"]}}}